Identification of non-PBP2a resistance mechanisms in Staphylococcus aureus after serial passage with ceftaroline: Involvement of other PBPs

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 11, 2016, Pages 3050-3057

  Lahiri, Sushmita D ^a,b   Alm, Richard A ^a,b  

^a ASTRAZENECA   (United Kingdom)

^b Macrolide Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFTAROLINE; CEFTAZIDIME; CEFTOBIPROLE; DRUG BINDING PROTEIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; METICILLIN; OXACILLIN; PENICILLIN BINDING PROTEIN 2; PENICILLIN BINDING PROTEIN 3; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; PENICILLIN BINDING PROTEIN;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; BACTERIUM MUTANT; CONTROLLED STUDY; GENE MUTATION; GENE OVEREXPRESSION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PROMOTER REGION; DNA MUTATIONAL ANALYSIS; DRUG EFFECTS; GENETIC SELECTION; GENETICS; GROWTH, DEVELOPMENT AND AGING; MICROBIAL SENSITIVITY TEST; MUTATION; STAPHYLOCOCCUS AUREUS; VIRUS CULTURE;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, BACTERIAL; MICROBIAL SENSITIVITY TESTS; MUTATION; PENICILLIN-BINDING PROTEINS; SELECTION, GENETIC; SERIAL PASSAGE; STAPHYLOCOCCUS AUREUS;

EID: 84994514897     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw282     Document Type: Article

References (32)

1. Kosowska-Shick K, McGhee PL, Appelbaum PC. Affinity of ceftaroline and other b-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents Chemother 2010; 54: 1670-7.
2. Ishikawa T, Matsunaga N, Tawada H et al. TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: Synthesis, physicochemical and pharmacological properties. Bioorg Med Chem 2003; 11: 2427-37.
3. Lahiri SD, McLaughlin RE, Whiteaker JD et al. Molecular characterization of MRSA isolates bracketing the current EUCAST ceftaroline-susceptible breakpoint for Staphylococcus aureus: the role of PBP2a in the activity of ceftaroline. J Antimicrob Chemother 2015; 70: 2488-98.
4. Hoban D, Biedenbach D, Sahm D et al. Activity of ceftaroline and comparators against pathogens isolated from skin and soft tissue infections in Latin America-results of AWARE surveillance 2012. Braz J Infect Dis 2015; 19: 596-603.
5. Alm RA, McLaughlin RE, Kos VN et al. Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: an epidemiological and structural perspective. J Antimicrob Chemother 2014; 69: 2065-75.
6. Biedenbach DJ, Hoban DJ, Reiszner E et al. In vitro activity of ceftaroline against Staphylococcus aureus isolates collected in 2012 from Latin American countries as part of the AWARE surveillance program. Antimicrob Agents Chemother 2015; 59: 7873-7.
7. Long SW, Olsen RJ, Mehta SC et al. PBP2a mutations causing high-level ceftaroline resistance in clinical methicillin-resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother 2014; 58: 6668-74.
8. Kelley WL, Jousselin A, Barras C et al. Missense mutations in PBP2A affecting ceftaroline susceptibility detected in epidemic hospital-acquired Staphylococcus aureus clonotypes ST228 and ST247 in western Switzerland archived since 1998. Antimicrob Agents Chemother 2015; 59: 1922-30.
9. Schaumburg F, Peters G, Alabi A et al. Missense mutations of PBP2a are associated with reduced susceptibility to ceftaroline and ceftobiprole in African MRSA. J Antimicrob Chemother 2016; 71: 41-4.
10. Clark C, McGhee P, Appelbaum PC et al. Multistep resistance development studies of ceftaroline in gram-positive and-negative bacteria. Antimicrob Agents Chemother 2011; 55: 2344-51.
11. Lahiri SD, Alm RA. Potential of Staphylococcus aureus isolates carrying different PBP2a alleles to develop resistance to ceftaroline. J Antimicrob Chemother 2016; 71: 34-40.
12. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-third Informational Supplement M100-S23. CLSI, Wayne, PA, USA, 2013.
13. Lahiri SD, Mangani S, Durant-Reville T et al. Structural insight into potent broad-spectrum inhibition with reversible recyclization mechanism: avibactam in complex with CTX-M-15 and Pseudomonas aeruginosa AmpC b-lactamases. Antimicrob Agents Chemother 2013; 57: 2496-505.
14. Chan LC, Basuino L, Diep B et al. Ceftobiprole-and ceftaroline-resistant methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2015; 59: 2960-3.
15. Reed P, Veiga H, Jorge AM et al. Monofunctional transglycosylases are not essential for Staphylococcus aureus cell wall synthesis. J Bacteriol 2011; 193: 2549-56.
16. Wang QM, Peery RB, Johnson RB et al. Identification and characterization of a monofunctional glycosyltransferase from Staphylococcus aureus. J Bacteriol 2001; 183: 4779-85.
17. Henze UU, Berger-Bachi B. Penicillin-binding protein 4 overproduction increases b-lactam resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1996; 40: 2121-5.
18. Henze UU, Berger-Bachi B. Staphylococcus aureus penicillin-binding protein 4 and intrinsic b-lactam resistance. Antimicrob Agents Chemother 1995; 39: 2415-22.
19. Farha MA, Leung A, Sewell EW, et al. Inhibition of WTA synthesis blocks the cooperative action of PBPs and sensitizes MRSA to b-lactams. ACS Chem Biol 2013; 8: 226-33.
20. Leski TA, Tomasz A. Role of penicillin-binding protein 2 (PBP2) in the antibiotic susceptibility and cell wall cross-linking of Staphylococcus aureus: evidence for the cooperative functioning of PBP2, PBP4, and PBP2A. J Bacteriol 2005; 187: 1815-24.
21. Davies TA, PageMG, ShangW, et al. Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae. Antimicrob Agents Chemother 2007; 51: 2621-4.
22. Mendes RE, Tsakris A, Sader HS et al. Characterization of methicillinresistant Staphylococcus aureus displaying increased MICs of ceftaroline. J Antimicrob Chemother 2012; 67: 1321-4.
23. Banerjee R, Gretes M, Basuino L et al. In vitro selection and characterization of ceftobiprole-resistant methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2008; 52: 2089-96.
24. Fernandez R, Paz LI, Rosato RR et al. Ceftaroline is active against heteroresistant methicillin-resistant Staphylococcus aureus clinical strains despite associated mutational mechanisms and intermediate levels of resistance. Antimicrob Agents Chemother 2014; 58: 5736-46.
25. Waxman DJ, Strominger JL. Penicillin-binding proteins and the mechanism of action of b-lactam antibiotics. Annu Rev Biochem 1983; 52: 825-69.
26. Wyke AW, Ward JB, Hayes MV et al. A role in vivo for penicillin-binding protein-4 of Staphylococcus aureus. Eur J Biochem 1981; 119: 389-93.
27. Curtis NAC, Hayes MV, Wyke AW et al. A mutant of Staphylococcus aureus H lacking penicillin-binding protein 4 and transpeptidase activity. FEMS Microbiol Lett 1980; 9: 263-6.
28. Navratna V, Nadig S, Sood V et al. Molecular basis for the role of Staphylococcus aureus penicillin binding protein 4 in antimicrobial resistance. J Bacteriol 2010; 192: 134-44.
29. Memmi G, Filipe SR, Pinho MG et al. Staphylococcus aureus PBP4 is essential for b-lactam resistance in community-acquired methicillinresistant strains. Antimicrob Agents Chemother 2008; 52: 3955-66.
30. Banerjee R, Gretes M, Harlem C et al. A mecA-negative strain of methicillin-resistant Staphylococcus aureus with high-level b-lactam resistance contains mutations in three genes. Antimicrob Agents Chemother 2010; 54: 4900-2.
31. Fishovitz J, Taghizadeh N, Fisher JF et al. The Tipper-Strominger hypothesis and triggering of allostery in penicillin-binding protein 2a of methicillinresistant Staphylococcus aureus (MRSA).J AmChemSoc 2015; 137: 6500-5.
32. Paulin S, Jamshad M, Dafforn TR et al. Surfactant-free purification of membrane protein complexes from bacteria: application to the staphylococcal penicillin-binding protein complex PBP2/PBP2a. Nanotechnology 2014; 25: 285101.